Clinical Trials

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07061977 2026-04-17

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT05256225 2026-04-16

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT06058377 2026-04-16

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06096844 2026-04-15

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

304 enrolled

Lung Neoplasms

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT01167712 2026-04-13

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04092283 2026-04-13

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04444921 2026-04-13

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

205 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT04579224 2026-04-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

184 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07198074 2026-04-13

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

255 enrolled

Endometrial Neoplasms

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT03801876 2026-04-03

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

474 enrolled

Phase 3 Not yet recruiting

Lung Neoplasms

NCT07441681 2026-04-03

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

454 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06998940 2026-03-27

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT04095364 2026-03-24

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05721755 2026-03-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

290 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

203 enrolled 22 charts

Phase 3 Not yet recruiting

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT07383922 2026-02-04

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

524 enrolled

Pancreatic Neoplasms

NCT03377491 2026-01-21

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

571 enrolled 22 charts

Pancreas Adenocarcinoma

NCT03768414 2026-01-12

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

452 enrolled 17 charts

Gallbladder Neoplasms, Cholangiocarcinoma

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

190 enrolled 12 charts

Breast Neoplasms

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05929768 2025-11-05

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

2,400 enrolled

Phase 3 Not yet recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT06018883 2025-08-07

PTCA199-3

100 enrolled

Classical hematology

Anemia

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

3,270 enrolled 16 charts

Breast Neoplasms

NCT07057427 2025-07-09

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

812 enrolled

Breast Neoplasms

NCT05116462 2025-06-26

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

506 enrolled